▸ 23 Oct 2026, 09:27 New Data Supports Biological Rationale for DMX-200 in FSGS Company Update
▸ 22 Oct 2026, 08:44 2026 AGM Notice of Meeting, Letter of Access and Proxy Form Meetings & Governance
▸ 19 Oct 2026, 08:30 Dimerix Announces Board Chair Transition Company Administration
▸ 16 Oct 2026, 08:52 DMX-200 First 100 Patients Complete Phase 3 Trial Treatment Company Update
▸ 12 Oct 2026, 08:32 Dimerix at Canaccord Drug & Device and Ignite Conferences Presentations
▸ 5 Oct 2026, 08:56 First Patient Reaches Four Years in DMX-200 Clinical Program Company Update
▸ 28 Sep 2026, 14:34 Notification regarding unquoted securities - DXB Securities Administration
▸ 25 Sep 2026, 14:42 Notification of 2026 Annual General Meeting Date Meetings & Governance
▸ 23 Sep 2026, 08:44 Dimerix Presents at ASX SMIDcaps Conference 2026 Presentations
▸ 23 Sep 2026, 08:36 Dimerix Draws Down A$17M Under Non-Dilutive Funding Facility Capital Raising
▸ 22 Sep 2026, 15:46 Waiver of Listing Rule 10.1 Granted Capital Raising
▸ 16 Sep 2026, 08:31 Dimerix Presents at E&P Healthcare Conference 2026 Presentations
▸ 14 Sep 2026, 08:39 Dimerix DMX-652 Granted Mexican Composition of Matter Patent Company Update
▸ 7 Sep 2026, 08:51 Dimerix Investor Presentation Presentations
▸ 4 Sep 2026, 17:10 S&P DJI Announces September 2026 Quarterly Rebalance Other
▸ 4 Sep 2026, 09:17 Dimerix Secures A$34 Million Non-Dilutive Funding Facility Capital Raising
▸ 2 Sep 2026, 08:43 Trading Halt Trading Halt / Suspension
▸ 27 Aug 2026, 08:56 Appendix 4G and Corporate Governance Statement Company Administration
▸ 27 Aug 2026, 08:56 Appendix 4E and 2026 Annual Report Financial Results
▸ 20 Aug 2026, 09:13 Dimerix Receives US$10M Upfront Payment from Everest Company Update
▸ 17 Aug 2026, 08:38 Dimerix Assumes Sponsorship of US IND for New Asset DMX-652 Company Update
▸ 6 Aug 2026, 08:17 Dimerix Presents at Bioshares Summit 2026 Presentations
▸ 30 Jul 2026, 08:49 Dimerix Quarterly Activities Report and Appendix 4C Quarterly Reports
▸ 27 Jul 2026, 08:36 Dimerix to Present at TechKnow Invest Conference 2026 Presentations
▸ 23 Jul 2026, 08:46 US Patent Granted for Dimerix New Asset DMX-652 Company Update
▸ 17 Jul 2026, 09:03 Dimerix Investor Webinar Presentations
▸ 17 Jul 2026, 09:03 Dimerix Expands Pipeline with Acquisition of Phase 2 Asset Company Update
▸ 17 Jul 2026, 09:01 Dimerix Non-Dilutive Funding Builds Pipeline, Boosts Runway Capital Raising
▸ 15 Jul 2026, 08:42 Trading Halt Trading Halt / Suspension
▸ 9 Jul 2026, 08:46 DMX-200 Available To Patients Via Post-Trial Access Pathways Company Update
▸ 16 Jun 2026, 10:31 Dimerix Investor Webinar Presentations
▸ 16 Jun 2026, 10:20 Dimerix Licenses DMX200 to Everest for China and Asia Region Company Update
▸ 15 Jun 2026, 09:13 Trading Halt Trading Halt / Suspension
▸ 30 Apr 2026, 09:13 Dimerix Quarterly Activities Report and Appendix 4C Quarterly Reports
▸ 28 Apr 2026, 10:26 Dimerix Releases Investor Presentation and Video Recording Company Update
▸ 28 Apr 2026, 09:20 ACTION3 Statistical Review Complete Company Update
▸ 9 Apr 2026, 14:01 Dimerix Singapore Investor Briefing Company Administration
▸ 16 Mar 2026, 09:20 Dimerix Presents at Euroz Hartleys Institutional Conference Presentations
▸ 16 Mar 2026, 08:29 Dimerix to Conduct Review of ACTION3 Statistical Assumptions Company Update
▸ 10 Mar 2026, 09:21 Dimerix Phase 3 Trial Last Patient Receives First Dose Company Update
▸ 4 Mar 2026, 09:38 Dimerix Invitation to Perth and Singapore Investor Briefings Company Administration
▸ 27 Feb 2026, 09:23 Dimerix Presents at Oppenheimer Life Sciences Conference Presentations
▸ 26 Feb 2026, 09:30 Appendix 4D and Half Year Financial Report Financial Results
▸ 5 Feb 2026, 09:26 Dimerix to Present at Euroz Hartleys Healthcare Forum 2026 Presentations
▸ 29 Jan 2026, 09:39 Quarterly Appendix 4C and Activities Report Quarterly Reports
▸ 21 Jan 2026, 08:28 Appointment of CFO/Company Secretary Company Administration
▸ 12 Jan 2026, 08:28 Clinical trial update at J.P. Morgan Healthcare Conference Presentations
▸ 24 Dec 2025, 08:36 Dimerix receives input from FDA on ACTION3 trial endpoints Company Update
▸ 22 Dec 2025, 09:16 BioMarin to acquire Dimerix US Partner, Amicus Therapeutics Company Update
▸ 15 Dec 2025, 08:45 DMX-200 ACTION3 Phase 3 Trial Completes Recruitment Company Update
▸ 12 Dec 2025, 14:50 Change of Director's Interest Notice - CS,HA,NW,SP & MD Director Interests
▸ 12 Dec 2025, 14:04 Notification regarding unquoted securities - DXB Securities Administration
▸ 19 Nov 2025, 09:05 Successful Completion of Planned IDMC Review Company Update
▸ 18 Nov 2025, 16:58 Results of AGM Meetings & Governance
▸ 18 Nov 2025, 12:58 Chair Address and AGM Presentation Presentations
▸ 29 Oct 2025, 08:35 Quarterly Appendix 4C and Activities Report Quarterly Reports
▸ 22 Oct 2025, 16:20 Cleansing Notice Securities Administration
▸ 22 Oct 2025, 16:13 Application for quotation of securities - DXB Securities Administration
▸ 21 Oct 2025, 08:31 Canaccord Drug & Device Conference Investor Presentation Presentations
▸ 16 Oct 2025, 09:03 2025 AGM Notice of Meeting, Letter of Access and Proxy Meetings & Governance
▸ 8 Oct 2025, 08:37 Successful PARASOL Collaboration Data Analysis Outcome Company Update
▸ 30 Sep 2025, 08:37 DMX-200 receives Orphan Drug Designation in Japan Company Update
▸ 19 Sep 2025, 09:32 Notification of Date of 2025 AGM Meetings & Governance
▸ 3 Sep 2025, 09:07 Investor Presentation Presentations
▸ 28 Aug 2025, 09:29 Appendix 4G and Corporate Governance Statement Company Administration
▸ 28 Aug 2025, 09:06 Appendix 4E and 2025 Annual Report Financial Results
▸ 19 Aug 2025, 08:57 Investor Presentation and Recording Presentations
▸ 12 Aug 2025, 15:08 Cleansing Notice Securities Administration
▸ 12 Aug 2025, 15:02 Application for quotation of securities - DXB Securities Administration
▸ 7 Aug 2025, 09:05 Dimerix presentation at Bioshares Biotech Summit Presentations